Shares of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) gained $17.76, or 13.3 percent, to close at $151.31 Tuesday after briefing documents posted by the FDA ahead of Thursday's meeting of the Gastrointestinal Drugs Advisory Committee (adcom) suggested a favorable review of the new drug application for obeticholic acid (OCA).